Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Alliance Pharma plc    APH   GB0031030819

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Alliance Pharma : first-half revenue rises on strong sales abroad

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2017 | 09:13am CEST

British speciality pharmaceutical company Alliance Pharma Plc (>> Alliance Pharma plc) on Wednesday reported an 8.4 percent rise in first-half revenue, helped by international sales of its scar reduction product and eye supplement.

British speciality pharmaceutical company Alliance Pharma Plc (>> Alliance Pharma plc) on Wednesday reported an 8.4 percent rise in first-half revenue, helped by international sales of its scar reduction product and eye supplement.

The company, listed on London's junior stock market, said revenue rose to 50.3 million pounds for the six months ended June 30, from 46.4 million pounds a year ago.

Underlying profit before tax rose 1.7 percent to 11.9 million pounds during the period.

Sales of the company's top-selling scar-diminishing product, Kelo-cote, rose to 6.2 million pounds in the first half from 4.1 million pounds a year ago.

MacuShield, the company's nutritional supplement to treat age-related vision loss, posted a 67 percent rise in first-half sales at 3.4 million pounds.

Alliance Pharma, which bought the healthcare assets of Sinclair Pharma (>> Sinclair Pharma PLC) for 128 million pounds in December 2015, now owns about 90 pharmaceutical and healthcare products.

"With the integration of the Sinclair Pharma products now complete we are strategically positioned for growth and, with leverage levels reducing, we are now able to pursue bolt-on acquisitions," Chairman Andrew Smith said.

Alliance Pharma said it believed there were grounds to re-open discussions with the UK's medicinal product regulator on Diclectin, a drug for nausea during pregnancy, which failed to receive approval earlier this year.

However, analysts have said the regulatory decision meant the company was also looking for a replacement for Diclectin.

The replacement is likely to come via acquisition or by obtaining licenses from other companies rather from within the current portfolio, analysts have said.

(Reporting By Justin George Varghese in Bengaluru; Editing by Amrutha Gayathri)

Stocks treated in this article : Alliance Pharma plc, Sinclair Pharma PLC
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLIANCE PHARMA PLC
09/14 ALLIANCE PHARMA : sales rise as key products inject healthy growth
09/13 ALLIANCE PHARMA : first-half revenue rises on strong sales abroad
09/08ALLIANCE PHARMA PLC : half-yearly earnings release
07/28 ALLIANCE PHARMA : Royal Bank Of Canada Sells Entire Alliance Pharma Shareholding..
07/18 ALLIANCE PHARMA : Half Year Trading Update
06/15 ALLIANCE PHARMA PLC : ex-dividend day for final dividend
04/07 Chelverton Growth Trust Outperforms Benchmark In First Half
03/30 ALLIANCE PHARMA : doubled
03/30 ALLIANCE PHARMA : Pharma giant in good health as sales double
03/29 ALLIANCE PHARMA : Dividend Rises 10% After Large Revenue, Profit Lifts
More news
Financials ( GBP)
Sales 2017 103 M
EBIT 2017 28,1 M
Net income 2017 23,4 M
Debt 2017 19,8 M
Yield 2017 2,42%
P/E ratio 2017 10,71
P/E ratio 2018 12,05
EV / Sales 2017 2,62x
EV / Sales 2018 2,42x
Capitalization 251 M
Chart ALLIANCE PHARMA PLC
Duration : Period :
Alliance Pharma plc Technical Analysis Chart | APH | GB0031030819 | 4-Traders
Technical analysis trends ALLIANCE PHARMA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 0,59  GBP
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
John Dawson CEO, Director & Head-Investor Relations
Andrew Leonard Smith Chairman
Stephen Kidner Chief Scientific & Operations Officer
Andrew Timothy Franklin Chief Financial Officer, Director & IR Contact
Thomas Theodore Casdagli Non-Executive Director
Sector and Competitors